CEA is still the antigen of choice to predict prognosis after CRC diagnosis and to monitor disease progression.18 T‐CEA expression is an important tumor marker in CRC, and elevated levels are associated with poorer prognosis. This evidence concerns the gene CEACAM5 and neoplasm.